Carol Jamieson

1.6k total citations
46 papers, 1.1k citations indexed

About

Carol Jamieson is a scholar working on Pharmacology, Experimental and Cognitive Psychology and Psychiatry and Mental health. According to data from OpenAlex, Carol Jamieson has authored 46 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Pharmacology, 15 papers in Experimental and Cognitive Psychology and 15 papers in Psychiatry and Mental health. Recurrent topics in Carol Jamieson's work include Treatment of Major Depression (20 papers), Mental Health Research Topics (11 papers) and Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes (9 papers). Carol Jamieson is often cited by papers focused on Treatment of Major Depression (20 papers), Mental Health Research Topics (11 papers) and Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes (9 papers). Carol Jamieson collaborates with scholars based in United States, Belgium and United Kingdom. Carol Jamieson's co-authors include Raymond C. Rosen, David L. Rowland, Stanley E. Althof, Pauline McNulty, Kai Fai Ho, Donald L. Patrick, Jon L. Pryor, Margaret Rothman, Chris G. McMahon and Gregory A. Broderick and has published in prestigious journals such as Gastroenterology, Cancer and The Journal of Urology.

In The Last Decade

Carol Jamieson

43 papers receiving 1.0k citations

Peers

Countries citing papers authored by Carol Jamieson

Since Specialization

Citations

This map shows the geographic impact of Carol Jamieson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carol Jamieson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carol Jamieson more than expected).

Fields of papers citing papers by Carol Jamieson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carol Jamieson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carol Jamieson. The network helps show where Carol Jamieson may publish in the future.

Co-authorship network of co-authors of Carol Jamieson

This figure shows the co-authorship network connecting the top 25 collaborators of Carol Jamieson. A scholar is included among the top collaborators of Carol Jamieson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carol Jamieson. Carol Jamieson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Intestinal LKB1 Loss Drives a Premalignant Program Along the Serrated Cancer Pathway 2025 ·Gastroenterology ·(unknown), H. Ma, Jelte van der Vaart, Joep Sprangers, Folkert H.M. Morsink, Despina Xanthakis, Carol Jamieson, (unknown), (unknown), (unknown), Tito Candelli, Roy Straver, (unknown), (unknown), Wendy W.J. de Leng, G. J. A. Offerhaus, Alessandra Merenda, Madelon M. Maurice	0
2	Assessment of health-related quality of life and health status in patients with treatment-resistant depression treated with esketamine nasal spray plus an oral antidepressant 2023 ·Health and Quality of Life Outcomes ·Carol Jamieson, Vanina Popova, Ella Daly, Kimberly Cooper, Wayne C. Drevets, Heather Rozjabek, Jaskaran Singh	7
3	Effects of esketamine on patient-reported outcomes in major depressive disorder with active suicidal ideation and intent: a pooled analysis of two randomized phase 3 trials (ASPIRE I and ASPIRE II) 2023 ·Quality of Life Research ·Carol Jamieson, Carla M. Canuso, Dawn F. Ionescu, Rosanne Lane, Xin Qiu, Heather Rozjabek, Patricio Molero, Dong‐Jing Fu	5
4	The relevance of fatigue to relapse rate in multiple sclerosis: Applying patient preference data to the OPTIMUM trial 2022 ·Multiple Sclerosis Journal ·Robert J. Fox, Tommi Tervonen, (unknown), (unknown), (unknown), Anne Brooks, Bryan T. Hennessy, Carol Jamieson, Bennett Levitan	2
5	Assessing the meaningful change threshold of Quality of Life in Depression Scale using data from two phase 3 studies of esketamine nasal spray 2022 ·Journal of Patient-Reported Outcomes ·Heather Rozjabek, Nan Li, Holger Hartmann, (unknown), Carla M. Canuso, Carol Jamieson	4
6	Use of Clinical Global Impressions-Severity (CGI-S) to Assess Response to Antidepressant Treatment in Patients with Treatment-Resistant Depression 2022 ·Neuropsychiatric Disease and Treatment ·Joachim Morrens, Maju Mathews, Vanina Popova, (unknown), Benoît Rive, (unknown), Carol Jamieson, Qiaoyi Zhang	12
7	Evaluation of Individual Items of the Patient Health Questionnaire (PHQ-9) and Montgomery-Asberg Depression Rating Scale (MADRS) in Adults with Treatment-Resistant Depression Treated with Esketamine Nasal Spray Combined with a New Oral Antidepressant 2022 ·CNS Drugs ·Lysbeth Floden, Stacie Hudgens, Carol Jamieson, Vanina Popova, Wayne C. Drevets, Kimberly Cooper, Jaskaran Singh	8
8	Development of a novel patient-reported outcome measure to assess signs and symptoms of COVID-19 2022 ·Journal of Patient-Reported Outcomes ·Carla DeMuro, Sheri Fehnel, Jeffrey J. Stoddard, Jerald Sadoff, Sandy Lewis, Pauline McNulty, Eric K. H. Chan, Emily Evans, Carol Jamieson, Ashley F. Slagle, Allen W. Mangel, Kelly McQuarrie	4
9	A novel disease specific scale to characterize the symptoms and impacts of fatigue in US adults with relapsing multiple sclerosis: A real-world study 2022 ·Multiple Sclerosis and Related Disorders ·(unknown), (unknown), (unknown), (unknown), Hoa H. Le, Carol Jamieson, Leigh Charvet, Lauren Krupp, Lindsey Lair	5
10	Comparison of Long-Term Efficacy and Safety of Esketamine Nasal Spray Plus Oral Antidepressant in Younger Versus Older Patients With Treatment-Resistant Depression: Post-Hoc Analysis of SUSTAIN-2, a Long-Term Open-Label Phase 3 Safety and Efficacy Study 2021 ·American Journal of Geriatric Psychiatry ·Rachel Ochs-Ross, Ewa Wajs, Ella Daly, Yun Zhang, Rosanne Lane, Pilar Lim, Wayne C. Drevets, David C. Steffens, Gerard Sanacora, Carol Jamieson, David Hough, Husseini K. Manji, Jaskaran Singh	27
11	U.S. Food and Drug Administration’s Patient-Focused Drug Development Initiative: Experience with Integration of Patient-Experience Data in a New Drug Application for Esketamine Nasal Spray Plus a Newly Initiated Oral Antidepressant for Treatment-Resistant Depression 2021 ·Therapeutic Innovation & Regulatory Science ·Eva G. Katz, Pauline McNulty, Bennett Levitan, (unknown), (unknown), Carol Jamieson	9
12	Meaningful Change in Depression Symptoms Assessed with the Patient Health Questionnaire (PHQ-9) and Montgomery-Åsberg Depression Rating Scale (MADRS) Among Patients with Treatment Resistant Depression in Two, Randomized, Double-blind, Active-controlled Trials of Esketamine Nasal Spray Combined With a New Oral Antidepressant 2020 ·Journal of Affective Disorders ·Stacie Hudgens, Lysbeth Floden, (unknown), Carol Jamieson, Vanina Popova, Maggie Fedgchin, Wayne C. Drevets, Kimberly Cooper, Rosanne Lane, Jaskaran Singh	45
13	Suicide Ideation and Behavior Assessment Tool (SIBAT): Evaluation of Intra- and Inter-Rater Reliability, Validity, and Mapping to Columbia Classification Algorithm of Suicide Assessment 2020 ·Psychiatry Research ·Larry Alphs, Dong‐Jing Fu, David J. Williamson, Ibrahim Turkoz, Carol Jamieson, Dennis A. Revicki, Carla M. Canuso	20
14	PND1 USE OF CLINICAL GLOBAL IMPRESSIONS-SEVERITY (CGI-S) TO ASSESS RESPONSE TO ANTIDEPRESSANT TREATMENT IN PATIENTS WITH TREATMENT-RESISTANT DEPRESSION 2020 ·Value in Health ·Joachim Morrens, Maju Mathews, Vanina Popova, (unknown), (unknown), (unknown), Carol Jamieson, (unknown)	0
15	Clinically meaningful changes on depressive symptom measures and patient‐reported outcomes in patients with treatment‐resistant depression 2020 ·Acta Psychiatrica Scandinavica ·Ibrahim Turkoz, Larry Alphs, Jaskaran Singh, Carol Jamieson, Ella Daly, M. Shawi, John J. Sheehan, Madhukar H. Trivedi, A. John Rush	42
16	Analysis of Clinical Trial Exit Interview Data in Patients with Treatment-Resistant Depression 2019 ·Patient ·Sandy Lewis, Carla DeMuro, Geert De Bruecker, James W. Murrough, Richard C. Shelton, Jaskaran Singh, Carol Jamieson	10
17	Interpretation of Change In Patient-Reported Outcomes in Treatment-Resistant Depression 2018 ·Value in Health ·Ibrahim Turkoz, Wing Chow, Larry Alphs, Jaskaran Singh, Pilar Lim, Richard Lane, Carol Jamieson, Allitia DiBernardo, M. Shawi, David Hough	1
18	Evidence to Support Montgomery-Asberg Depression Rating Scale Administration Every 24 Hours to Assess Rapid Onset of Treatment Response 2016 ·The Journal of Clinical Psychiatry ·Kristen Johnson, Jacob Devine, Kai Fai Ho, Kellee Howard, (unknown), Carol Jamieson	12
19	Capecitabine plus docetaxel combination therapy 2005 ·Cancer ·Shailendra Verma, D Maraninchi, Joyce O’Shaughnessy, Carol Jamieson, Stephen E. Jones, Miguel Martín, Joseph McKendrick, David Miles, Chris Twelves, John Hornberger	18
20	Ambulatory blood pressure in heart failure 2001 ·European Journal of Clinical Investigation ·M. J. Jamieson, Carol Jamieson	7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact